At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 61 enrolled
Drug / intervention
Atazanavir + Ritonavirdrug
Likely dose
Atazanavir + Ritonavir 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IIIb Multicenter, Single Arm, Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance With Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Infected Patients Evidencing Virologic Suppression OREY (Only REYataz) Study
In Brief
A Phase 3 clinical trial evaluating Atazanavir + Ritonavir for Human Immunodeficiency Virus (HIV) Infections. Completed, enrolled 61 participants across 7 sites.
Detailed Summary
The main purpose is to explore whether atazanavir/ritonavir (ATV/RTV) single enhanced protease inhibitor therapy can maintain virologic suppression without a marked increase in virologic failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSpain
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJun 2006
Primary CompletionMay 2008
Study CompletionMay 2009
TodayJul 2026
First PostedJun 16, 2006
Enrollment StartJun 1, 2006
Primary CompletionMay 1, 2008
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 20.0 years ago
Interventions
Atazanavir + Ritonavirdrug
Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks